

Adenosine 2A Receptor (A2AR) **Antagonism and AIH in ALS Study**

Researchers at the University of Florida are testing a therapeutic strategy to delay breathing problems in those with amyotrophic lateral sclerosis (ALS). This strategy combines an FDA-approved medication (Istradefylline) with a breathing intervention (AIH).

What is AIH?

Acute Intermittent Hypoxia (AIH) is repeated cycles of lowered oxygen air (9-10% O₂) alternated with periods of normal room air (21% O₂). The decrease in oxygen with AIH is somewhat like the decreases in oxygen found when travelling from sea level to high altitude. For example, spending one minute at the peak of Mt. Denali would produce a similar effect on breathing to what is used in AIH. Studies have shown AIH can be delivered safely and seems to assist with rehabilitation.

Contact Us:

Principal Investigator: Dr. Barbara Smith PT, PhD

Bksmith@phhp.ufl.edu

Study Coordinator: JuliaPrascak@ufl.edu

About this study

- 1 short screening visit to test eligibility
- 4 study visits, ~2 weeks apart
- Each visit includes either AIH or normal air
- One dose of Istradefylline or Placebo (sugar pill) assigned randomly to each visit
- Blood tests, plus breathing and strength measurements at each study visit
- Compensation of up to \$500 for participation

Are you eligible?

- Adults 21-80 years old
- Healthy or ALS diagnosis
- Not using a breathing machine while awake
- Other eligibility criteria also apply

Location

Clinical and Translational Research Institute – University of Florida, Gainesville, FL

UF | FLORIDA

College of Public Health & **Health Professions – Physical Therapy**

IRB202101568

A2A Study Study Coor (352) 273-0	
udy oord 73-68	

••	1200 0000	Study Coordinator:	A2A Study	
		or:		

(352) 273-6855	Study Coordinator:	A2A Study

(352) 273-6855	Study Coordinator	A2A Study
	9	

(35)	Stı	A2A
52) 273-6855	Study Coordi	2A Study
355	inato	

(352) 273-6855	Study Coordinato	A2A Study
----------------	------------------	-----------